Drug Discovery, Design and Development

Alexander O. Terent’ev was born in Moscow, in 1973. He received his M.S. in Chemistry of Biologically Active Compounds from D. Mendeleev University of Chemical Technology of Russia, Moscow. PhD degree (2000) and D.Sc. degree (2009) in Organic Chemistry in N.D. Zelinsky Institute of Organic Chemistry RAS. 2011 – Professor D. Mendeleev University of Chemical Technology of Russia. 2016 – Professor RAS. Head of laboratory in N.D. Zelinsky Institute of Organic Chemistry RAS, Head of laboratory in All-Russian Research Institute of Phytopathology. fe He published 3 chapters in books, 100 research papers, and 25 patents

Dr. Jadhav is responsible for strategic, scientific planning and business functions for the organization. He also act as an expert and contribute to the clinical development plans, target product profile for the  clinical and scientific development projects e.g. NCE, 505(b)(2) across different therapeutic areas e.g. infectious diseases, oncology, autism, Huntington disease, CV, CNS etc. He has supported 08 pre-IND meetings, IND compilations for US-FDA communications for small molecules, synthetic peptides and biological.

Dr. Jadhav brings in his experience of over 10+ years in industry and academia. He is a trained clinical pharmacologist with extensive experience in planning, designing, execution and interpretation of clinical studies (prospective, retrospective, interventional and observational) in the area of cancer, cardiovascular and infectious diseases.

He was part of successful team which developed first Indian liposomal amphotericin B (Fungisome^TM) and launched in Indian market. Dr. Jadhav has over twenty-five peer-reviewed publications, co-edited a book, have made numerous posters and oral presentations internationally.

Dr. Jadhav received his PhD in Pharmaceutics from Bombay College of Pharmacy and KEM Hospital, University of Mumbai, India and did his Post-Doctoral fellowship at the Colleges of Pharmacy and Medicine Univ. of Florida, Gainesville, Florida.

Amrik has a PhD in biochemistry/protein engineering from the university of leicester after which he spent 6 years at the Institute of Biotechnology, Cambridge University investigating bacterial pathways involved with the metabolism of illicit drugs and high explosives. In 2002, Amrik joined domantis Ltd developing domain antibodies. Following the acquisition of domantis by GSK, he became head of topical delivery (Biopharm Discovery Unit), supporting the development of biotherapeutics for delivery into the eye, skin and lung. In 2013 he joined Avacta as chief scientific officer to develop the Affimer platform for therapeutic use.

Rashid Mahmood has master degree in analytical chemistry and MS in total quality management. He has 15 years of experience of pharmaceutical quality operations and has participated in many international conferences as a keynote speaker. He has presented various talks in USA, Canada, UK & UAE on cleaning validation, cGMP guidelines, quality risk management,role of mass spectrometry in pharmaceuticals and on new drug delivery dystems. Currently he is working as a General manager technical operations for Surge Lab. which is the best export oriented company of pakistan..

Wayne J M Karim, is from Yokohama-city University Hospital, Yokohama, Japan.He has completed his studies for Bachelor of Science in Biology at the University of California, Riverside , and his studies for Master of Science in Medicinal Chemistry at the University of San Francisco. During his tenure at both universities, he served as an instructor for organic chemistry laboratory courses, and as a lead technician for botanical and chemical research laboratories.

Zakir has completed her PhD from Jamia Hamdard (NIRF rank 1), India. Dr. Zakir is currently working as an Asst. Prof., Delhi Pharmaceutical Sciences and Research University (India’s First Pharmacy University and second in the world). She has more than 20 referred articles in high impact journals >4 (h-index=9, >400 citations). She has authored numerous book chapters by Elsevier and Bentham publishers. She has published more than 50 conference proceedings and abstracts. Zakir has received research funding of 20,00,00 INR from Department of Science and Technology. She has received Award for Academic Excellence in 2010.

Madhu Gupta is working as an Associate Professor in Delhi Pharmaceutical Science and Research University, New Delhi. She has research experience pertaining to drug delivery to nanoformulations for magical molecule delivery, bioligands for targeting of bioactives and drug moiety, biopolymers, cancer nanomedicine as well as topical delivery that is carried out at Department of Pharmaceutical Sciences, Dr. H.S. Gour Central University, Sagar. She has over 80 research publications to her credit published in journals of high scientific impact and contributed 30 chapters in various renowned books and to several international and national books. She has the recipient of Research Excellence of the Year 2020, Youth Education Icon of the Year 2018, Young Scientist Award, Best Administrative Service Award, IDMA-G.P. Nair award and Prof. C.S. Chauhan award. She has also filed the PCT patent for effective wound healing therapy. She has the awardees of various national and International conference in the form of best oral and poster presentation award. as APTI and other. She has also organized so many National and international Conferences.

Wu Mingshu Alicia who works as quality & safety and patient experience director in a private cancer hospital in Guangzhou China. She has rich experience in greenfield hospital setting ups and quality & safety management. She successful led JCI & TUV accreditation for a high-end private women & children’s hospital in 2017.

Frank studied Chemistry at the University Hamburg, Germany and the University Sevilla, Spain. He received his PhD from Hamburg University while working at the Max-Planck Working Groups for Structural Biology at Deutsches Elektron-Synchrotron (DESY) on the elucidation of the functional kinesin dimer. After his PhD he moved to France where he worked for 10 years at the French Atomic Commission (CEA) on human kinesins. In 2007 he joined the Beatson Institute for Cancer Research, Cancer Research UK, as a senior group leader and became professor at Glasgow Medical School. He was responsible for setting up the structural biology department used by several goups. In 2013 Frank was appointed Chair in Pharmaceutical and Biological Chemistry at the UCL School of Pharmacy in London. His current research interests involve members of the kinesin superfamily as potential targets for drug development.